Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Jun 10, 2022 2:33pm
283 Views
Post# 34747875

RE:Patients 20 & 21

RE:Patients 20 & 21Hi 99942Apophis - You're right - as of May 28, 2021 only 19 patients had been treated and on June 11, 2021 it was announced that the 20th patient had been treated. So the 20th patient won't reach 450 days until somewhere between August 21st and September 4th 2022.

In the MD&A before showing the table of results for the first 20 patients it says:

"An analysis of the first 20 patients treated in Study II (completed all assessment visits), provides the following interim analysis:"

Patient 20 has not yet completed his/her 450 day assessment visit.

What could this mean? Could this be a table of the first 20 patients that have received all of the assessment visits they are eligible for? In other words, the first 20 patients who are not "no response" and so are no longer being assessed? 

99942Apophis wrote: Patient 20 announced June 11/2021 just hit 360 days and although patients 21 to 24 were announced August 30/2021 my guesstimate is patient 21 will hit 360 days very close to the AGM.
By years end (2022) we should see 24 patients hitting 450 days with a strong possibility of patient 25 getting in too.


<< Previous
Bullboard Posts
Next >>